登入選單

返回Google圖書搜尋

Real-world Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma After Prior Therapy: Interim Results from the Noninterventional NORA Study

Marc-Oliver GrimmViktor GrünwaldHarald Müller-HuesmannPhilipp IvanyiMartin SchostakEyck von der HeydeWolfgang Schultze-SeemannHanjo BelzMartin BögemannMeng WangMartin HerberJens Bedke[Study Group] NORA Study Group

出版	Universität, 2022
URL	http://books.google.com.hk/books?id=M7qlzwEACAAJ&hl=&source=gbs_api

註釋

Abstract: Background
Nivolumab monotherapy is approved for the treatment of advanced renal cell carcinoma (aRCC) after prior therapy on the basis of results from CheckMate 025.

Objective
The NORA (NivOlumab in Renal cell cArcinoma) noninterventional study (NIS) aims to capture real-world data to complement the pivotal CheckMate 025 clinical trial.

Design, setting, and participants
NORA is a prospective, multicenter NIS in Germany. Consenting patients with aRCC of any subtype who started nivolumab after previous therapy were eligible.

Outcome measurements and statistical analysis
The primary objective was to estimate overall survival (OS) in the overall population and relevant subgroups. Secondary objectives included progression-free survival (PFS), the objective response rate (ORR), the duration of response (DOR), safety, and patient-reported outcomes (PROs). Baseline characteristics were summarized using descriptive statistics. OS and PFS were estimated via the Kaplan-Meier-method.

Results and limitations
A total of 228 patients with aRCC were eligible. The median age was 70 yr, 71% were male, 14% had favorable, 58% had intermediate, and 15% had poor International Metastatic RCC Database Consortium risk (12% missing information). The median follow-up was 37 mo. In the overall population, median OS was 24 mo (95% confidence interval [CI] 19-28) and median PFS was 5.3 mo (95% CI 3.9-6.7). The ORR was 20% and the median DOR was 28 mo (95% CI 16-not estimable). No new safety signals emerged (46% and 15% of patients had treatment-related adverse events of all grades and grade 3-4, respectively; there was 1 treatment-related death due to liver failure). PROs did not reveal detriments during the study duration. Limitations include the lack of central pathology review and no standardization for imaging evaluation and toxicity assessment.

Conclusions
Effectiveness and safety in this real-world population were in line with the pivotal clinical trial and support the use of nivolumab after prior systemic therapy in a broad aRCC population